The E1912 follow-up analysis shows that ibrutinib-based therapy lived longer and with sustained benefit in previously untreated CLL patients. The majority of patients were well-tolerated, with only 14% stopping due to side effects.
The TAILORx trial has shown that women with high Recurrence Scores (26-100) have a 93% chance of being cancer-free after five years, with those receiving chemotherapy having a significantly better outcome. The findings support the use of adjuvant chemotherapy to improve treatment outcomes in early breast cancer patients.
ECOG-ACRIN announces late-breaking TAILORx data on chemotherapy regimens for early-stage breast cancer. The data, published concurrently in JAMA Oncology, focuses on patients with a score of 26-100 on the 21-tumor gene recurrence score assay.
A new study published in The Journal of Clinical Oncology found that FDG-PET/CT imaging achieved true negatives in 94% of patients, suggesting its potential to assist clinicians in deciding on the best therapy for clinically N0 necks. This could lead to prevented patient morbidity and cost savings.
The NCI-MATCH trial found a combination of dabrafenib and trametinib to be effective in treating patients with BRAF mutations across 17 distinct tumor types, including several rare cancer types. The treatment showed promising activity outside of currently approved FDA indications.
A pre-specified secondary analysis of the TAILORx trial found that assessing a woman's recurrence risk based on classic clinical features adds prognostic information complementary to the 21-gene Recurrence Score test. This integration may help identify young women who can forego chemotherapy and those who may benefit from more effectiv...
The ECOG-ACRIN Cancer Research Group's phase three trial, E2810, found that pazopanib treatment did not improve disease-free survival in Stage IV patients with no evidence of disease following a surgery to remove the metastases. Average survival for these patients is about two to three years and long-term survival is uncommon.
The new TAILORx trial data reveals racial disparities in breast cancer outcomes, with 83.1% white women alive and cancer-free after nine years, compared to 78.9% black women. The study suggests biological factors contribute to the differences, regardless of treatment type or duration.
The combination of ibrutinib plus rituximab was superior to standard treatment in improving progression-free survival and overall survival for patients with chronic lymphocytic leukemia. The treatment also showed fewer serious side effects compared to the standard FCR regimen.
The NCI-MATCH trial has released new findings on three arms of the trial, showing promise in patients with rare genetic changes. The study's results suggest that future studies could see more responses in populations with earlier-stage disease.
The TAILORx trial found no benefit from chemotherapy for 70% of women with hormone receptor-positive, HER2-negative breast cancer. Treatment with hormone therapy alone after surgery was as effective as hormone therapy plus chemotherapy in reducing invasive disease-free survival and overall survival.
The NCI-MATCH trial has released findings from three treatment arms, offering hope for targeted therapies in patients with specific gene abnormalities. The trial's results could aid in identifying effective treatments for various cancers, paving the way for future research.
A simple blood test detecting tumor cells in blood may predict high or low risk of breast cancer relapse. The study found that 5% of cancer-free women had a positive CTC test, associated with a 35% recurrence risk after two years.
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is a randomized trial comparing two types of digital mammography for breast cancer screening. The study aims to determine if the newer technology, tomosynthesis (3D), reduces advanced breast cancers more effectively than conventional mammography.
The NCI-MATCH precision medicine cancer treatment trial has reached its goal of sequencing the tumors of 6,000 patients two years ahead of schedule. This is due to wide-scale adoption throughout the NCTN and NCORP networks, resulting in an unprecedented rate of patient enrollment.
The ECOG-ACRIN Cancer Research Group is recruiting medical facilities for the Tomosynthesis Mammography Imaging Screening Trial (TMIST), a large-scale breast cancer screening trial comparing digital breast tomosynthesis with standard digital mammography. The study aims to provide a modern basis for continued use of mammography.
A new study assesses the effectiveness of self-guided online genetic education in reducing anxiety and stress among cancer patients undergoing tumor gene testing. Researchers hope to improve patients' experience with precision medicine by increasing knowledge about test limitations and benefits.
The TAILORx trial found that 99.3% of patients with low Oncotype DX scores had no distant recurrence at 5 years after treatment with hormonal therapy alone. This study provides evidence supporting the clinical utility of Oncotype DX to risk-stratify patients with early stage breast cancer.
The ECOG-ACRIN Cancer Research Group has opened the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) phase II precision medicine trial. The trial seeks to enroll approximately 3,000 adults with solid tumors or lymphoma who have returned or worsened after standard therapy.
A new phase III trial will examine two treatment sequences for advanced melanoma patients, with half receiving an investigational combination of immunotherapy drugs first and the other half receiving a different sequence. Researchers aim to find the best treatment sequence to extend patient survival.
A phase three trial found that using sunitinib or sorafenib after surgery did not reduce recurrence in high-risk renal cell carcinoma patients, compared to standard care. The study, E2805, involved 1943 patients and demonstrated no significant differences in disease-free survival or overall survival between treatment groups.
A new clinical trial is exploring the use of breast MRI and genomic testing to guide treatment decisions for women with ductal carcinoma in situ (DCIS) breast cancer. The study aims to determine whether MRI findings can reduce the number of unnecessary mastectomies, a common concern among patients with DCIS.